Diffuse large B-cell lymphoma
Conditions
Interventions
Intervention group:D-R-GDP
Sponsors
Union Medical College Affiliated Hospital of Tongji Medical College, Huazhong University of Science and Technology
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. The age ranged from 18 to 75 years with no gender restriction; ECoG score was 0-2; the expected survival time was > 12 weeks; 2. In patients with diffuse large B-cell lymphoma confirmed by pathology, CD20 was positive; 3. 4 cycles of first-line treatment with rituximab and anthracycline, patients with positive PET evaluation of PR; 4. Patients without chemotherapy contraindications: hemoglobin >= 9.0g/dl, neutrophil count >= 1500 / UL, platelet >= 100000 / UL, ALT and AST <= 2 times of normal upper limit, serum total bilirubin <= 1.5 times normal upper limit value, serum creatinine <= 1.5 times normal upper limit value; 5. Patients with at least one measurable lesion; 6. The patients without other serious diseases in conflict with this scheme had normal cardiopulmonary function; 7. The results of urine or blood pregnancy test for women of childbearing age within 7 days after enrollment were negative. The male and female patients should agree to use effective contraceptive measures during the treatment period and the following year; 8. Patients who can understand the study and sign informed consent before screening.
Exclusion criteria
Exclusion criteria: 1. Patients who are not newly treated or relapsed; 2. Patients with double hit lymphoma; 3. Patients who have been treated with past abnormal methylation inhibitors; 4. Patients with central nervous system involvement (meninges or parenchyma); 5. Patients who plan to receive subsequent autologous stem cell transplantation; 6. Patients who refuse to provide blood and tissue samples; 7. Patients who have received more than one chemotherapy regimen in the past; 8. Patients with peripheral neuropathy >= grade 2; 9. Patients with drug allergy or metabolic disorders to the drugs in this protocol; 10. Those who refuse to take reliable contraceptive methods during pregnancy, lactation or school age; 11. Patients with any uncontrollable medical diseases (including uncontrolled diabetes mellitus, severe heart, lung, liver, and kidney dysfunction); 12. Patients with severe infection or active bleeding; 13. Patients with contraindications to chemotherapy or targeted therapy; 14. Patients with other malignant tumors in the past; 15. Mental disorders / patients without informed consent; 16. Patients who were not suitable to participate in the study were determined by the researchers.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| CR;PR;ORR; | — |
Countries
China
Contacts
Public ContactLiling Zhang
Cancer Center of Union Medical College Affiliated Hospital of Tongji Medical College, Huazhong University of Science and Technology
Outcome results
None listed